$ELV

Dixon Robert L JR sold $61K of ELV

Dixon Robert L JR sold 151 shares of Elevance Health, Inc. (ELV) at $401.77 on 2026-06-11.

Original reporting
SEC EDGAR · Dixon Robert L JR
Published Jun 12, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ELV
Neutral
high confidence
Mentioned
$ELV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELVNeutralLow
01

Why it matters

The disclosure documents an open-market sale by a director; it does not include any new company performance, guidance, or regulatory/legal development.

02

Market read

Traders may note the insider sale, but the transaction size and lack of accompanying fundamental news make it unlikely to drive a sustained repricing.

03

What to watch

Director sales can be driven by diversification, taxes, or personal liquidity; without additional context, the signal-to-noise is low.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-12 for a sale executed 2026-06-11

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Elevance Health, Inc.

Company-level read

Ticker impact

$ELVNeutralHigh confidence
Context

Elevance Health director Robert L. Dixon Jr. filed an open-market sale of 151 shares at ~$401.77 on 2026-06-11 (Form 4).

Expected impact

Minimal near-term impact; any effect is likely noise unless paired with other negative disclosures.

Evidence & confidence

This is a small, non-10b5-1 open-market sale by a director with no accompanying company-specific catalyst or guidance change in the text.

Market effects

No sector read-through; single-company insider transaction with no operational/regulatory update.

None indicated.

None indicated.

Counterpoint

Because the filing notes no pre-arranged 10b5-1 plan, some traders may interpret it as a modest negative signal, even if the dollar amount is small.

Key entities

  • Elevance Health, Inc.

    Subject of the Form 4 insider transaction disclosure (ELV).

  • Robert L. Dixon Jr.

    Director who sold 151 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ELVMed

Cantor Fitzgerald keeps Elevance stock rating on Medicare concerns

Cantor Fitzgerald maintained an Overweight rating and $450 price target for Elevance Health (ELV) despite a decline in its 2027 Medicare Stars ratings. The firm expects pressure on the stock due to concerns around Medicare Advantage management. Elevance reaffirmed its 2026 earnings guidance, projecting at least $20.10 per diluted share. Analysts have mixed views, with Guggenheim raising its target to $455 and RBC lowering it to $424.

$CNCHigh

ACA fraud crackdown threatens health insurer profits in 2026

Vice President JD Vance announced 760,000 ACA enrollees were dropped due to fraud, with 400,000 under review. Insurers like Centene, Molina, Elevance, and UnitedHealth saw stock declines. Experts warn of squeezed margins in 2026-2027 due to a less healthy risk pool. Premium rates for 2027 are locked, and insurers may push for higher 2028 rates. Brokers, who drive 75% of sign-ups, face new restrictions and potential reputational damage.